Dunhill Financial’s Novavax NVAX Stock Holding History

Dunhill Financial’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40	Hold	4	–	–	﹤0.01%	1538
2026 Q1	$34	Hold	4	–	–	﹤0.01%	1690
2025 Q4	$29	Buy	+4	New	+$30	﹤0.01%	1832

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Dunhill Financial's NVAX Position: Q2 2026 in Review

Dunhill Financial held its Novavax (NVAX) position steady in Q2 2026 at 4 shares worth $40. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Dunhill Financial first reported a position in NVAX in Q4 2025 and has held it in 3 quarters since. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Dunhill Financial held 4 shares of Novavax worth $40 as of Q2 2026.
Dunhill Financial left its Novavax share count unchanged in Q2 2026.
Novavax made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1538 holding.
Dunhill Financial first reported a position in Novavax in Q4 2025 and has held it in 3 quarters since.
266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.